Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology March 1, 2024 Mehdi Sekssaoui, Joël Bockaert, Philippe Marin et al. 76 citations
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the...